Question to the Department for Science, Innovation & Technology:

To ask His Majesty's Government what is the total value of known life-sciences investments in the UK that have been cancelled or paused since 4 July 2024.

Through delivery of the Life Sciences Sector Plan, and the wider Industrial Strategy, this Government is taking targeted action to address the global challenges that life sciences companies face and unlock economic growth. Challenges include global competition and global commercial uncertainty.

Our ambition is that the UK will be the leading Life Sciences economy in Europe by 2030 and the third most important globally, behind the US and China only, by 2035. We have already started delivering on key actions, investing up to £600 million in the Health Data Research Service alongside Wellcome, committing over £650 million in Genomics England and up to £354 million in Our Future Health, and launching the £50 million Life Sciences Transformational R&D Investment Fund pilot.

Alongside these commitments, we have continued to see transformative investments into the UK made by Life Sciences companies. For example: in May 2025, BioNTech committed up to £1 billion as part of a ten-year investment on top of their existing strategic partnership with the Government; in August, Eli Lilly invested £35 million in the Obesity Pathway Innovation Programme; and in October, Convatec announced plans to invest £500 million in a new R&D facility in Manchester.